TRANSFORMING CANCER CARE

Ilumira: The Lu-177 patients deserve

Patients worldwide rely on lutetium-177 (Lu-177) radioligand therapies for conditions like advanced prostate cancer and neuroendocrine cancers¹.

MADE DIFFERENTLY TO MAKE A DIFFERENCE

High purity Ilumira - Lutetium(¹⁷⁷Lu) chloride

Not all Lu-177 is created the same. Carrier-added forms contain impurities that dilute effectiveness and create more waste. SHINE’s llumira is non-carrier-added Lu-177 with ≥99.9% purity, precisely targeting tumors and minimizing unnecessary radiation. That level of purity gives you greater confidence in every vial.

Inquire About Our Products

Fill out the form or call us at 608.210.1060

PURITY IN PRACTICE

What ≥99.9% purity means for care

n.c.a. Lu-177 purity at this level translates into clear, practical advantages. Here’s what it means for patients and providers:

Effective irradiation

The higher specific activity of n.c.a. Lu-177 compared to c.a. Lu-177 ensures greater availability of radioactivity thus reducing the mass of non-radioactive carrier material administered.²

Reliable preparation

Consistent labeling yields (≈90-99% vs ≈5-90% for c.a.) support predictable results across patients and programs.

Lower waste burden

n.c.a. Lu-177 has a short half-life and negligible long-lived impurities, simplifying hospital storage and disposal.

Precision in Practice

How llumira targets cancer

We supply llumira n.c.a. Lu-177 as a chloride solution in treated glass vials. Paired with a targeting molecule, it becomes a radiopharmaceutical that delivers therapeutic radiation where it’s needed most, while minimizing harm to healthy tissue. For patients who have exhausted other options, llumira offers new hope for cancer care³.

TWO PATHS, ONE CLEAR CHOICE

Carrier-added vs. Non-carrier-added Lu-177²

	Carrier-Added (C.A.)	Non-Carrier-Added (N.C.A.)
Composition	Lu-177 plus non-therapeutic isotopes (Lu-176, Lu-177m)	≥99.9% Lu-177
Specific Activity	Lower, variable (≈370–1110 GBq/mg)	Higher, consistent (up to ≈3700 GBq/mg)
Drug Preparation	Inconsistent labeling yields (≈5–90%)	Consistent labeling yields (≈90–99%)
Clinical Impact	Less efficient tumor binding → more residual isotope, higher side-effect risk	More efficient tumor binding → less residual isotope, lower side-effect risk
Waste Containment	Long-lived impurities (e.g., Lu-177m, t½ ≈160 days) require extended storage and handling	Waste decays quickly (t½ ≈6.65 days), negligible long-lived contamination

QUALITY SECURED, SUPPLY ASSURED

Production to delivery: The llumira advantage

Quality & compliance

llumira achieves ≥99.9% purity, meeting both U.S. and European Pharmacopoeia standards. Every batch is tested to confirm radiolabeling yield and performance, ensuring predictable results. Produced under cGMP standards and supported by an FDA Drug Master File, llumira delivers consistency you can trust.

Supply & reliability

With weekly shipping, customers can place
an order one week and receive it the next,
keeping research and clinical trials on schedule. SHINE’s U.S.-based facility is
scaled to support hundreds of thousands
of doses each year. Streamlined logistics
and experience in international shipping
further reduce delays and disruptions.

Independence & security

We’re involved in every step of the process, from securing enriched Yb-176 through final shipment, for a secure and reliable supply. SHINE is one of the few lutetium producers that also recycles ytterbium (Yb-176) thus reducing waste, improving efficiency, and de-risking supply. Made in the U.S. and ready for the world, llumira strengthens providers’ resilience everywhere.

MORE THAN A SUPPLIER

Reliable support and expertise

SHINE offers dependable service that goes beyond supply. We test every lot to confirm quality and performance, coordinate timely delivery, and provide radiolabeling insight as needed. Weekly shipping keeps programs moving, and our expertise is always within reach.

llumira Product Specifications⁵

Packaging Options	10 mL flat bottom glass vial 2mL conical glass vial
Chemical form	n.c.a. ¹⁷⁷LuCl₃ in 0.04M HCl solution
Specific activity	≥3,000 GBq/mg at SHINE calibration time
Radiochemical Purity	≥99% as ¹⁷⁷LuCl₃
Radionuclidic Purity	≥99.9% ¹⁷⁷Lu
Radioactivity Concentration at SHINE Calibration Time	1.0 Ci/mL ± 10% (37 GBq/mL)
Expiry	10 days from the end of synthesis
Standard Calibration Time	Tuesdays 1200 Central Time (U.S.) at 1.0 Ci/mL
cGMP	Meets ICH Q7, U.S. and EU GMP standards*
*ICH Q7, applicable provisions of FDA 21 CFR Parts 210 and 211, and European Commission EudraLex Volume 4 GMP Guidelines and applicable Annexes

A bright path for cancer care

llumira n.c.a. Lu-177 is produced with 99.9% purity at SHINE’s cGMP U.S. facility. That gives CDMOs, researchers, and providers consistency they can count on. Higher purity supports better radiolabeling, targeted elimination of cancer cells, reduced exposure to unnecessary radiation, and
patient care that stays on schedule.

Ready to advance your targeted cancer therapies?

REFERENCES

1. Niu T, Fan M, Lin B, et al. Current clinical application of lutetium-177 in solid tumors (Review). Exp Ther Med. 2024;27(5):225. doi:10.3892/etm.2024.12514. PMID: 38596660; PMCID: PMC11002837. Accessed April 30, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC11002837

2. Dash A, Pillai MR, Knapp FF Jr. Production of 177Lu for targeted radionuclide therapy: available options. Nucl Med Mol Imaging. 2015;49(2):85–107. doi:10.1007/s13139-014-0315-z. PMCID: PMC4463871. Accessed April 30, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC4463871/

3. Nanabala R, Pillai MRA, Gopal B. Preparation of patient doses of [177Lu]Lu-DOTATATE and [177Lu]Lu-PSMA-617 with carrier added (CA) and no carrier added (NCA) 177Lu. Nucl Med Mol Imaging. 2022;56(6):313–322. doi:10.1007/s13139-022-00778-y. Accessed April 30, 2026.

4. World Nuclear Association. Radioisotopes in medicine. World Nuclear Association Information Library. Accessed April 30, 2026. https://world-nuclear.org/information-library/non-power-nuclear-applications/radioisotopes-research/radioisotopes-in-medicine

5. Data on file at SHINE

Note: Illumira is a radiopharmaceutical precursor, not a finished drug. It is solely intended for radiolabeling of carrier molecules and is not for direct patient use.